Results 101 to 110 of about 5,265 (145)

Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae

, 2017
Zika virus (ZIKV) causes significant public health concerns because of its association with congenital malformations, neurological disorders in adults, and, more recently, death.
Priscila de Paiva Silva, Patrícia A. Reis, Reis, Patricia Alves, Mayara Mattos, Vieira, Yasmine Rangel, Carolina Sacramento, André C. Ferreira, Bozza, Fernando A., Hugo C. de Castro Faria Neto, Silva, Priscila de Paiva, Ferreira, André C., Yasmine Rangel Vieira, Camila Zaverucha-do-Valle, Bozza, Patrícia Torres, Fernando A. Bozza, Sacramento, Carolina, Bozza, Patrícia T., Giselle Barbosa-Lima, Loraine Campanati, Thiago Moreno L. Souza, Souza, Thiago Moreno L., Brüning, Karin, Karin Brüning, Amilcar Tanuri, Faria Neto, Hugo C. de Castro, Tanuri, Amilcar, Mattos, Mayara, Campanati, Loraine, Lima, Giselle Barbosa, Valle, Camila Zaverucha do, Patrícia T. Bozza   +30 more
core   +1 more source

Sofosbuvir: a novel oral agent for chronic hepatitis C

, 2020
Major changes have emerged during the last few years in the therapy of patients with chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been developed showing potent activity against hepatitis C virus (HCV) and incrementally ...
Evangelos Cholongitas, George V Papatheodoridis   +1 more
core  

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

ClinicoEconomics and Outcomes Research, 2015
David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat ...
Walker DR, Juday TR, Manthena SR, Jing Y, Sood V   +4 more
doaj  

Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C

, 2018
To appraise the clinical and cost effectiveness of sofosbuvir velpatasvir voxilaprevir within its marketing authorisation for treating chronic hepatitis ...
Onyimadu, Oluchukwu, Harris, Petra, Kalita, Neelam, Cooper, Keith, Picot, Joanna   +4 more
core   +1 more source

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with ...
Kwo, Paul Y., Agarwal, Kosh, Muir, Andrew J., Buti, Maria, Symonds, William T., Mo, Hongmei, Afdhal, Nezam, Jacobson, Ira M., Marcellin, Patrick, Pang, Philip S., Foster, Graham R., Mangia, Alessandra, Chojkier, Mario, Ding, Xiao, Romero Gomez, Manuel, Yang, Jenny C., Zarski, Jean Pierre, Bräu, Norbert, Gitlin, Norman, Puoti, Massimo, Buggisch, Peter, Forns, Xavier, Subramanian, G.Mani, Zeuzem, Stefan, McHutchison, John G.   +24 more
core  

Characterization and Insights into the Formation of New Multicomponent Solid Forms of Sofosbuvir

Sofosbuvir, a drug used for the treatment of hepatitis C, is known to have several polymorphs. However, its ability to form multicomponent solid forms has been little researched, and only the crystal structure of one cocrystal has been reported until ...
Jan Rohlíček (1797028), Eliska Skorepova (9719389), Jan Jirat (12321177), Miroslav Šoóš (4025402), Argyro Chatziadi (4426159)   +4 more
core   +1 more source

Sofosbuvir [PDF]

Reactions Weekly, 2016
Publicaciones CIMEFil: Sola, Nancy. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas; Argentina.Este Boletín está estructurado con una introducción general del ingrediente farmacéutico activo sofosbuvir, su aprobación en Argentina y la ...
Sola, Nancy
core   +8 more sources

Some of the next articles are maybe not open access.

Related searches:

Sofosbuvir

Reactions Weekly, 2018
  +10 more sources

Sofosbuvir

Reactions Weekly, 2017
  +6 more sources

Ribavirin/sofosbuvir/sofosbuvir/velpatasvir

Reactions Weekly, 2021
openaire   +1 more source